Related references
Note: Only part of the references are listed.A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma
Alba A. Brandes et al.
ONCOLOGIST (2019)
Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
J. N. Jakobsen et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine
Shinichi Komiyama et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2018)
Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
Jie Song et al.
ONCOTARGETS AND THERAPY (2018)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials
Giuseppe Lombardi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
D. H. Heiland et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Lale Erdem-Eraslan et al.
CANCER RESEARCH (2016)
The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma
Christina Schaub et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Novel angiogenesis inhibitors in nonsmall cell lung cancer
Niels Reinmuth et al.
CURRENT OPINION IN ONCOLOGY (2015)
Bevacizumab and Glioblastoma: Scientific Review, Newly Reported Updates, and Ongoing Controversies
Kathryn M. Field et al.
CANCER (2015)
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Walter Taal et al.
LANCET ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts
Veronique Lorgis et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More.?
John F. de Groot
CLINICAL CANCER RESEARCH (2011)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model
Kristoph Jahnke et al.
NEURO-ONCOLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Share Paper
